Relative effectiveness of high-dose versus standard-dose influenza vaccine against hospitalizations and mortality according to Charlson Comorbidity Index: A post-hoc analysis of the DANFLU-1 randomized trial
The lower incidences of clinical outcomes for HD-IV compared to SD-IV were not significantly modified by CCI. The potential benefit of HD-IV versus SD-IV may therefore be applicable regardless of comorbidity burden. Further research is required to confirm these findings.
Authors
- Joshua Nealon (ORCID: https://orcid.org/0000-0003-1538-4636)
- Theis Skovsgaard Itenov (ORCID: https://orcid.org/0000-0002-1204-3636)
- Daniel Modin (ORCID: https://orcid.org/0000-0002-7566-0519)
- Signe Tellerup Nielsen (ORCID: https://orcid.org/0000-0001-5674-7902)
- Lene Russel
- Nino Emanuel Landler
- Niklas Dyrby Johansen
- Caroline Espersen
- Jens Ulrik Stæhr Jensen
- Katrine Feldballe Bernholm
- Matthew M. Loiacono
- Lars Køber
- Martin J. Landray
- Carsten Schade Larsen
- Brian L. Claggett
- Rebecca C. Harris
- Anne Marie Reimer Jensen
- Scott D. Solomon
- Pradeesh Sivapalan
- Gunnar H. Gislason
- Sandrine Samson
- Kira Janstrup Hyldekær
- Tor Biering-Sørensen
Institutions
- University of Copenhagen (DK)
- Brigham and Women's Hospital (US)
- Steno Diabetes Centers (DK)
- Harvard University (US)
- University of Southern Denmark (DK)
- Frederiksberg Hospital (DK)
- Aarhus University Hospital (DK)
- Copenhagen University Hospital (DK)
- Gentofte Hospital (DK)
- Sanofi (France) (FR)
- University of Oxford (GB)
- Sanofi (United States) (US)
- Swift Engineering (United States) (US)
Publication Details
- Journal
- European Journal of Clinical Microbiology & Infectious Diseases
- Published
- 2026-01-29
- DOI
- https://doi.org/10.1007/s10096-026-05408-5
- Primary Topic
- Influenza Virus Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00